Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1997-07-09
2000-04-04
Bawa, Raj
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424490, 424494, A61K 914
Patent
active
060458291
ABSTRACT:
The present invention describes formulations of nanoparticulate HIV protease inhibitors comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of dissolution in vitro, an increase rate of absorption in vivo, a decreased fed/fasted ratio variability, and a decreased variability in absorption. The present invention is also directed to methods of making the novel formulations. In particular, nanoparticulate formulations of HIV type 1 (HIV-1) and type 2 (HIV-2) protease inhibitors are described.
REFERENCES:
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5429824 (1995-07-01), June
patent: 5518187 (1996-05-01), Bruno et al.
patent: 5518738 (1996-05-01), Eickhoff et al.
patent: 5622938 (1997-04-01), Wong
De Garavilla et al., Chemical Abstracts, vol. 126, 1996.
Ruddy et al., Chemical Abstracts, vol. 125, #257225, 1996.
"The Protease Inhibitors Backgrounder," Office of Special Health Issues and Division of Antiviral Drug Products, Food and Drug Adminsitration (1998).
Physicians' Desk Reference, 53.sup.rd Edition, "Invirase.TM.; Saquinavir mesylate," pp. 2685-2688, Medical Economics Co., (1999).
Physicians' Dest Reference, 53.sup.rd Edition, "Fortovase.TM.; Saquinavir," pp. 2675-2681, Medical Economics Co., (1999).
Physicians' Dest Reference, 53.sup.rd Edition, "Norvir.TM.; Ritonavir," 464-469, Medical Economics Co., (1999).
Physicians' Dest Reference, 53.sup.rd Edition, "Viracept.RTM.; Nelfinavir," 484-487, Medical Economics Co., (1999).
M. Markowitz, "Protease Inhibitors" pp. 2, 7, International Association of Physicians in AIDS Care, (1997).
Physicians' Dest Reference, 53.sup.rd Edition, "Crixivan.RTM.; Indinavir," 1762-1766, Medical Economics Co., (1999).
Structure-Based Design of Novel HIV Protease Inhibitors: Sulfonamide-Containing 4-Hydroxycoumarins and 4-Hydroxy-2-pyrones as Potent Non-Peptidic Inhibitors, Suvit Thaisrivongs, et al., J. Med. Chem, 1996, 39, 2400-2410.
Engers David A.
Liversidge Gary G.
Roberts Mary E.
Ruddy Stephen B.
Wong Sui-Ming
Bawa Raj
Elan Pharma International Limited
LandOfFree
Nanocrystalline formulations of human immunodeficiency virus (HI does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nanocrystalline formulations of human immunodeficiency virus (HI, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanocrystalline formulations of human immunodeficiency virus (HI will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-362544